Linda Watkins
Concepts (966)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuralgia | 41 | 2026 | 143 | 11.730 |
Why?
| | Hyperalgesia | 71 | 2026 | 131 | 11.620 |
Why?
| | Toll-Like Receptor 4 | 46 | 2023 | 276 | 8.200 |
Why?
| | Pain | 61 | 2021 | 781 | 7.550 |
Why?
| | Microglia | 55 | 2024 | 255 | 7.150 |
Why?
| | Rats, Sprague-Dawley | 241 | 2026 | 2525 | 6.880 |
Why?
| | Spinal Cord | 50 | 2023 | 376 | 6.010 |
Why?
| | Rats | 283 | 2026 | 5637 | 5.810 |
Why?
| | Morphine | 41 | 2020 | 172 | 5.570 |
Why?
| | Neuroglia | 39 | 2015 | 173 | 4.740 |
Why?
| | Neuroimmunomodulation | 35 | 2025 | 67 | 4.530 |
Why?
| | Interleukin-10 | 23 | 2024 | 310 | 3.920 |
Why?
| | Analgesics, Opioid | 38 | 2019 | 1123 | 3.860 |
Why?
| | Animals | 365 | 2026 | 37749 | 3.310 |
Why?
| | Chronic Pain | 10 | 2026 | 280 | 3.240 |
Why?
| | Cytokines | 53 | 2024 | 2100 | 3.150 |
Why?
| | Interleukin-1beta | 33 | 2023 | 386 | 2.950 |
Why?
| | Interleukin-1 | 51 | 2011 | 973 | 2.860 |
Why?
| | Spinal Cord Injuries | 9 | 2021 | 232 | 2.800 |
Why?
| | Stress, Psychological | 60 | 2020 | 1133 | 2.780 |
Why?
| | Inflammation | 51 | 2024 | 2902 | 2.580 |
Why?
| | Sciatic Neuropathy | 13 | 2023 | 32 | 2.510 |
Why?
| | Behavior, Animal | 55 | 2020 | 516 | 2.510 |
Why?
| | Lymphocyte Antigen 96 | 12 | 2019 | 24 | 2.460 |
Why?
| | Lipopolysaccharides | 52 | 2023 | 889 | 2.440 |
Why?
| | Signal Transduction | 42 | 2025 | 5169 | 2.390 |
Why?
| | Genetic Therapy | 16 | 2024 | 315 | 2.310 |
Why?
| | Injections, Spinal | 39 | 2018 | 108 | 2.290 |
Why?
| | Pain Threshold | 23 | 2019 | 75 | 2.270 |
Why?
| | Central Nervous System | 13 | 2018 | 265 | 2.250 |
Why?
| | Hippocampus | 51 | 2020 | 940 | 2.210 |
Why?
| | Stress, Physiological | 45 | 2017 | 454 | 2.040 |
Why?
| | Pain Measurement | 37 | 2024 | 554 | 2.040 |
Why?
| | Narcotic Antagonists | 20 | 2020 | 192 | 2.010 |
Why?
| | Corticosterone | 33 | 2019 | 242 | 1.980 |
Why?
| | Inflammasomes | 9 | 2023 | 142 | 1.980 |
Why?
| | Inflammation Mediators | 16 | 2020 | 519 | 1.820 |
Why?
| | Analgesia | 13 | 2015 | 102 | 1.810 |
Why?
| | Naltrexone | 19 | 2023 | 102 | 1.800 |
Why?
| | Encephalomyelitis, Autoimmune, Experimental | 5 | 2021 | 68 | 1.780 |
Why?
| | Male | 286 | 2026 | 70179 | 1.750 |
Why?
| | Raphe Nuclei | 30 | 2014 | 109 | 1.750 |
Why?
| | Adenosine A2 Receptor Agonists | 4 | 2018 | 24 | 1.720 |
Why?
| | Disease Models, Animal | 46 | 2024 | 4421 | 1.660 |
Why?
| | HIV Envelope Protein gp120 | 12 | 2010 | 61 | 1.620 |
Why?
| | Vagus Nerve | 16 | 2001 | 89 | 1.550 |
Why?
| | Fear | 34 | 2020 | 347 | 1.510 |
Why?
| | Plasmids | 9 | 2024 | 365 | 1.510 |
Why?
| | Sciatic Nerve | 11 | 2024 | 63 | 1.480 |
Why?
| | Peripheral Nervous System Diseases | 10 | 2012 | 132 | 1.470 |
Why?
| | Naloxone | 16 | 2019 | 129 | 1.410 |
Why?
| | Prefrontal Cortex | 20 | 2018 | 316 | 1.390 |
Why?
| | HMGB1 Protein | 12 | 2019 | 50 | 1.390 |
Why?
| | Helplessness, Learned | 21 | 2012 | 68 | 1.340 |
Why?
| | Brain | 34 | 2024 | 2868 | 1.310 |
Why?
| | Immune System | 9 | 2026 | 183 | 1.270 |
Why?
| | Minocycline | 8 | 2017 | 27 | 1.260 |
Why?
| | Encephalitis | 10 | 2018 | 137 | 1.250 |
Why?
| | Neurons | 26 | 2022 | 1621 | 1.200 |
Why?
| | Receptors, Interleukin-1 | 17 | 2016 | 215 | 1.190 |
Why?
| | Electroshock | 61 | 2018 | 143 | 1.160 |
Why?
| | Astrocytes | 10 | 2019 | 217 | 1.160 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 11 | 2023 | 164 | 1.150 |
Why?
| | Glucocorticoids | 17 | 2019 | 534 | 1.130 |
Why?
| | Tumor Necrosis Factor-alpha | 27 | 2019 | 1250 | 1.110 |
Why?
| | Serotonin | 32 | 2020 | 323 | 1.110 |
Why?
| | Peripheral Nerve Injuries | 5 | 2023 | 38 | 1.100 |
Why?
| | Conditioning, Classical | 11 | 2020 | 108 | 1.090 |
Why?
| | Piperidines | 5 | 2018 | 218 | 1.090 |
Why?
| | Escape Reaction | 25 | 2014 | 58 | 1.090 |
Why?
| | Somatosensory Cortex | 3 | 2026 | 42 | 1.080 |
Why?
| | Pain Management | 8 | 2021 | 396 | 1.060 |
Why?
| | Toll-Like Receptor 2 | 7 | 2021 | 120 | 1.060 |
Why?
| | Nucleus Accumbens | 9 | 2019 | 151 | 1.030 |
Why?
| | Dependovirus | 2 | 2024 | 77 | 1.030 |
Why?
| | Central Nervous System Stimulants | 6 | 2019 | 178 | 1.010 |
Why?
| | Memory Disorders | 15 | 2020 | 182 | 0.990 |
Why?
| | Osteoarthritis | 2 | 2020 | 199 | 0.920 |
Why?
| | Dose-Response Relationship, Drug | 41 | 2023 | 2064 | 0.910 |
Why?
| | Conditioning, Operant | 13 | 2017 | 103 | 0.900 |
Why?
| | Escherichia coli Infections | 15 | 2014 | 117 | 0.900 |
Why?
| | Acute Pain | 1 | 2026 | 55 | 0.890 |
Why?
| | Low-Level Light Therapy | 1 | 2024 | 5 | 0.880 |
Why?
| | MicroRNAs | 3 | 2021 | 692 | 0.880 |
Why?
| | RNA, Messenger | 26 | 2017 | 2828 | 0.860 |
Why?
| | Dopamine | 8 | 2019 | 309 | 0.850 |
Why?
| | Circadian Rhythm | 8 | 2019 | 515 | 0.840 |
Why?
| | Ventral Tegmental Area | 4 | 2019 | 60 | 0.840 |
Why?
| | Glucuronides | 2 | 2014 | 19 | 0.840 |
Why?
| | Vagotomy | 15 | 2001 | 34 | 0.830 |
Why?
| | Fever | 11 | 2011 | 308 | 0.830 |
Why?
| | Alarmins | 5 | 2018 | 27 | 0.830 |
Why?
| | Posterior Horn Cells | 2 | 2019 | 10 | 0.820 |
Why?
| | Ganglia, Spinal | 6 | 2016 | 88 | 0.820 |
Why?
| | Psoriasis | 1 | 2024 | 111 | 0.810 |
Why?
| | Narcotics | 8 | 2014 | 55 | 0.800 |
Why?
| | Cocaine | 5 | 2023 | 173 | 0.790 |
Why?
| | Motor Activity | 21 | 2023 | 720 | 0.780 |
Why?
| | Physical Stimulation | 13 | 2014 | 68 | 0.780 |
Why?
| | Aging | 16 | 2021 | 1924 | 0.770 |
Why?
| | Pyridines | 7 | 2017 | 557 | 0.760 |
Why?
| | Morphine Derivatives | 2 | 2014 | 19 | 0.760 |
Why?
| | Analysis of Variance | 27 | 2018 | 1321 | 0.750 |
Why?
| | Toll-Like Receptors | 6 | 2017 | 189 | 0.750 |
Why?
| | Chemokines, CX3C | 4 | 2005 | 10 | 0.740 |
Why?
| | Drug Delivery Systems | 5 | 2024 | 363 | 0.730 |
Why?
| | Rats, Inbred F344 | 19 | 2018 | 269 | 0.710 |
Why?
| | Methamphetamine | 3 | 2019 | 67 | 0.710 |
Why?
| | Drug Tolerance | 6 | 2017 | 105 | 0.710 |
Why?
| | Time Factors | 42 | 2019 | 6966 | 0.710 |
Why?
| | Sciatica | 6 | 2012 | 7 | 0.690 |
Why?
| | Phenethylamines | 2 | 2018 | 19 | 0.670 |
Why?
| | Anti-Inflammatory Agents | 4 | 2018 | 482 | 0.670 |
Why?
| | Migraine Disorders | 3 | 2017 | 107 | 0.670 |
Why?
| | Amygdala | 10 | 2017 | 192 | 0.660 |
Why?
| | Interleukin-6 | 15 | 2014 | 792 | 0.640 |
Why?
| | Nociceptors | 8 | 2006 | 41 | 0.640 |
Why?
| | Nicotinic Agonists | 2 | 2012 | 136 | 0.640 |
Why?
| | Arthralgia | 1 | 2020 | 57 | 0.630 |
Why?
| | Anxiety | 15 | 2020 | 1090 | 0.630 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 14 | 2012 | 255 | 0.630 |
Why?
| | Laparotomy | 5 | 2020 | 115 | 0.610 |
Why?
| | Gene Expression Regulation | 19 | 2019 | 2608 | 0.600 |
Why?
| | Substance-Related Disorders | 4 | 2024 | 1102 | 0.600 |
Why?
| | Defecation | 1 | 2019 | 19 | 0.590 |
Why?
| | Chronobiology Disorders | 1 | 2018 | 16 | 0.590 |
Why?
| | Reactive Oxygen Species | 2 | 2016 | 634 | 0.590 |
Why?
| | Receptors, Nicotinic | 2 | 2012 | 344 | 0.580 |
Why?
| | Adenosine | 2 | 2018 | 253 | 0.580 |
Why?
| | Neural Pathways | 13 | 2026 | 308 | 0.570 |
Why?
| | Synapses | 1 | 2022 | 429 | 0.570 |
Why?
| | Spinal Cord Dorsal Horn | 3 | 2019 | 5 | 0.570 |
Why?
| | Multiple Sclerosis | 4 | 2021 | 470 | 0.570 |
Why?
| | Sex Characteristics | 5 | 2018 | 792 | 0.550 |
Why?
| | Humans | 95 | 2026 | 141754 | 0.540 |
Why?
| | Neurons, Afferent | 4 | 2007 | 101 | 0.540 |
Why?
| | Neuroprotective Agents | 3 | 2015 | 142 | 0.540 |
Why?
| | Ethanol | 5 | 2014 | 629 | 0.530 |
Why?
| | Immunity, Innate | 14 | 2019 | 852 | 0.530 |
Why?
| | Trigeminal Caudal Nucleus | 1 | 2017 | 1 | 0.530 |
Why?
| | Contusions | 1 | 2017 | 21 | 0.530 |
Why?
| | Proto-Oncogene Proteins c-fos | 14 | 2018 | 191 | 0.520 |
Why?
| | Facial Nerve Injuries | 1 | 2016 | 3 | 0.520 |
Why?
| | Macrophages | 11 | 2017 | 1562 | 0.520 |
Why?
| | Reactive Nitrogen Species | 1 | 2016 | 19 | 0.510 |
Why?
| | Membrane Proteins | 5 | 2010 | 1158 | 0.510 |
Why?
| | Spinal Injuries | 1 | 2017 | 57 | 0.510 |
Why?
| | Facial Nerve | 1 | 2016 | 39 | 0.510 |
Why?
| | Exercise Movement Techniques | 1 | 2016 | 7 | 0.510 |
Why?
| | Catheters, Indwelling | 3 | 2012 | 90 | 0.490 |
Why?
| | Reward | 8 | 2015 | 256 | 0.490 |
Why?
| | Cells, Cultured | 17 | 2020 | 4212 | 0.490 |
Why?
| | Memory | 10 | 2018 | 263 | 0.490 |
Why?
| | DNA | 6 | 2024 | 1444 | 0.490 |
Why?
| | NADPH Oxidases | 1 | 2016 | 140 | 0.490 |
Why?
| | Reaction Time | 17 | 2012 | 432 | 0.490 |
Why?
| | Cyclic AMP-Dependent Protein Kinases | 2 | 2014 | 129 | 0.480 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2018 | 226 | 0.480 |
Why?
| | Xanthines | 2 | 2014 | 23 | 0.470 |
Why?
| | Catheterization | 6 | 2007 | 182 | 0.470 |
Why?
| | Hindlimb | 3 | 2013 | 134 | 0.470 |
Why?
| | Excitatory Amino Acid Transporter 2 | 2 | 2016 | 15 | 0.460 |
Why?
| | Liver | 6 | 2019 | 1820 | 0.460 |
Why?
| | Dorsal Raphe Nucleus | 4 | 2020 | 31 | 0.450 |
Why?
| | Microinjections | 19 | 2018 | 86 | 0.450 |
Why?
| | Paralysis | 2 | 2015 | 70 | 0.450 |
Why?
| | Endotoxins | 5 | 2012 | 220 | 0.450 |
Why?
| | Xenobiotics | 1 | 2015 | 32 | 0.440 |
Why?
| | Resilience, Psychological | 3 | 2018 | 133 | 0.430 |
Why?
| | Gliosis | 4 | 2013 | 28 | 0.430 |
Why?
| | Fatigue | 1 | 2016 | 339 | 0.420 |
Why?
| | Chronic Disease | 11 | 2017 | 1820 | 0.410 |
Why?
| | T-Lymphocytes | 2 | 2021 | 2007 | 0.410 |
Why?
| | Neuropharmacology | 1 | 2013 | 5 | 0.410 |
Why?
| | Gonadal Steroid Hormones | 1 | 2014 | 139 | 0.400 |
Why?
| | Disease | 4 | 1999 | 102 | 0.400 |
Why?
| | Glucuronic Acid | 1 | 2013 | 25 | 0.400 |
Why?
| | Corticotropin-Releasing Hormone | 7 | 2005 | 75 | 0.400 |
Why?
| | Hot Temperature | 10 | 2009 | 406 | 0.390 |
Why?
| | Quinuclidines | 1 | 2012 | 9 | 0.390 |
Why?
| | Allergy and Immunology | 1 | 2013 | 41 | 0.390 |
Why?
| | HSP90 Heat-Shock Proteins | 2 | 2010 | 47 | 0.380 |
Why?
| | Myeloid Differentiation Factor 88 | 5 | 2014 | 105 | 0.380 |
Why?
| | Injections, Intraperitoneal | 16 | 2009 | 114 | 0.370 |
Why?
| | Arthritis, Rheumatoid | 1 | 2021 | 1178 | 0.370 |
Why?
| | Estradiol | 2 | 2014 | 528 | 0.370 |
Why?
| | Models, Animal | 1 | 2014 | 396 | 0.370 |
Why?
| | Facial Pain | 1 | 2012 | 13 | 0.370 |
Why?
| | Exploratory Behavior | 7 | 2018 | 91 | 0.370 |
Why?
| | Thiophenes | 1 | 2012 | 127 | 0.370 |
Why?
| | Protein Kinase C | 1 | 2013 | 252 | 0.370 |
Why?
| | Hyperesthesia | 3 | 2007 | 6 | 0.360 |
Why?
| | Mice | 24 | 2024 | 18109 | 0.360 |
Why?
| | Neuralgia, Postherpetic | 1 | 2012 | 40 | 0.360 |
Why?
| | NF-kappa B | 8 | 2019 | 692 | 0.350 |
Why?
| | Complement System Proteins | 2 | 2005 | 333 | 0.350 |
Why?
| | Brain-Derived Neurotrophic Factor | 6 | 2009 | 141 | 0.350 |
Why?
| | Gram-Negative Bacterial Infections | 1 | 2011 | 49 | 0.350 |
Why?
| | Animals, Newborn | 14 | 2019 | 870 | 0.350 |
Why?
| | CD11b Antigen | 6 | 2010 | 63 | 0.340 |
Why?
| | Female | 36 | 2026 | 75943 | 0.340 |
Why?
| | Drug-Seeking Behavior | 2 | 2023 | 23 | 0.330 |
Why?
| | Avoidance Learning | 5 | 2018 | 74 | 0.330 |
Why?
| | Pyrazoles | 7 | 2017 | 482 | 0.330 |
Why?
| | Diet, High-Fat | 3 | 2017 | 253 | 0.330 |
Why?
| | Ceftriaxone | 1 | 2010 | 20 | 0.330 |
Why?
| | Heterocyclic Compounds, 3-Ring | 1 | 2010 | 37 | 0.320 |
Why?
| | Indolizines | 6 | 2017 | 11 | 0.320 |
Why?
| | Chemokines | 3 | 2021 | 228 | 0.320 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 11 | 2012 | 987 | 0.320 |
Why?
| | Receptor, Adenosine A2A | 1 | 2009 | 23 | 0.310 |
Why?
| | Genetic Vectors | 4 | 2024 | 336 | 0.310 |
Why?
| | Morphinans | 3 | 2015 | 8 | 0.310 |
Why?
| | Receptors, Opioid, mu | 6 | 2020 | 70 | 0.310 |
Why?
| | Constriction, Pathologic | 4 | 2016 | 241 | 0.310 |
Why?
| | Self Administration | 5 | 2023 | 126 | 0.310 |
Why?
| | Up-Regulation | 4 | 2013 | 860 | 0.310 |
Why?
| | Meninges | 2 | 2006 | 43 | 0.300 |
Why?
| | Respiratory Insufficiency | 2 | 2014 | 325 | 0.300 |
Why?
| | Formaldehyde | 6 | 2013 | 67 | 0.300 |
Why?
| | Sialoglycoproteins | 8 | 2004 | 160 | 0.300 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 8 | 2012 | 855 | 0.300 |
Why?
| | Neurotransmitter Agents | 2 | 2006 | 81 | 0.290 |
Why?
| | Cell Line | 13 | 2019 | 2887 | 0.290 |
Why?
| | Behavior | 3 | 2006 | 93 | 0.290 |
Why?
| | Endothelial Cells | 1 | 2014 | 816 | 0.290 |
Why?
| | Mice, Inbred BALB C | 7 | 2014 | 1275 | 0.290 |
Why?
| | Functional Laterality | 7 | 2016 | 242 | 0.290 |
Why?
| | Injections, Subcutaneous | 9 | 2012 | 166 | 0.280 |
Why?
| | Parkinson Disease | 1 | 2014 | 571 | 0.280 |
Why?
| | Receptors, Tumor Necrosis Factor | 3 | 2004 | 166 | 0.280 |
Why?
| | HEK293 Cells | 6 | 2024 | 737 | 0.280 |
Why?
| | Glutamic Acid | 1 | 2010 | 256 | 0.280 |
Why?
| | Cerebral Cortex | 4 | 2018 | 462 | 0.280 |
Why?
| | Face | 1 | 2009 | 175 | 0.280 |
Why?
| | Wakefulness | 1 | 2009 | 172 | 0.280 |
Why?
| | Microdialysis | 13 | 2012 | 54 | 0.280 |
Why?
| | Receptors, Opioid | 3 | 2011 | 27 | 0.280 |
Why?
| | Receptors, Immunologic | 3 | 2019 | 215 | 0.270 |
Why?
| | Molecular Dynamics Simulation | 3 | 2019 | 246 | 0.270 |
Why?
| | Transgenes | 2 | 2024 | 186 | 0.270 |
Why?
| | Receptors, Complement | 2 | 2005 | 122 | 0.270 |
Why?
| | Substance Withdrawal Syndrome | 5 | 2011 | 185 | 0.270 |
Why?
| | Drug Design | 2 | 2010 | 168 | 0.270 |
Why?
| | Constriction | 3 | 2023 | 47 | 0.270 |
Why?
| | Clozapine | 2 | 2018 | 21 | 0.270 |
Why?
| | Cues | 8 | 2013 | 324 | 0.270 |
Why?
| | Biomedical Research | 2 | 2013 | 708 | 0.270 |
Why?
| | Hypothalamus | 5 | 2008 | 155 | 0.260 |
Why?
| | Crotalid Venoms | 2 | 2004 | 30 | 0.260 |
Why?
| | Alkaline Phosphatase | 3 | 2014 | 149 | 0.260 |
Why?
| | Drug Administration Schedule | 7 | 2019 | 771 | 0.260 |
Why?
| | Locomotion | 2 | 2018 | 107 | 0.260 |
Why?
| | Phospholipases A | 2 | 2004 | 104 | 0.260 |
Why?
| | Nitric Oxide | 7 | 2019 | 900 | 0.260 |
Why?
| | Mycobacterium | 2 | 2018 | 112 | 0.260 |
Why?
| | Chemokine CX3CL1 | 5 | 2008 | 25 | 0.260 |
Why?
| | Immunocompetence | 1 | 2006 | 44 | 0.250 |
Why?
| | Cognition | 6 | 2018 | 1228 | 0.250 |
Why?
| | Nerve Tissue Proteins | 5 | 2011 | 605 | 0.250 |
Why?
| | Transfection | 3 | 2018 | 943 | 0.250 |
Why?
| | Limbic System | 3 | 2019 | 52 | 0.250 |
Why?
| | Dinoprostone | 4 | 2014 | 191 | 0.250 |
Why?
| | Immunohistochemistry | 17 | 2010 | 1739 | 0.250 |
Why?
| | Citrates | 6 | 2006 | 41 | 0.240 |
Why?
| | Corpus Striatum | 3 | 2018 | 177 | 0.240 |
Why?
| | Ketamine | 3 | 2018 | 111 | 0.240 |
Why?
| | Extinction, Psychological | 5 | 2023 | 88 | 0.240 |
Why?
| | Cisterna Magna | 4 | 2013 | 8 | 0.240 |
Why?
| | Neuronal Plasticity | 3 | 2022 | 305 | 0.240 |
Why?
| | Freezing Reaction, Cataleptic | 4 | 2013 | 22 | 0.240 |
Why?
| | Hypothalamo-Hypophyseal System | 5 | 2012 | 207 | 0.240 |
Why?
| | Adaptation, Psychological | 2 | 2010 | 681 | 0.240 |
Why?
| | Paclitaxel | 1 | 2006 | 237 | 0.230 |
Why?
| | Oxycodone | 3 | 2019 | 48 | 0.230 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2006 | 192 | 0.230 |
Why?
| | Bacterial Infections | 4 | 2009 | 245 | 0.230 |
Why?
| | DNA-Binding Proteins | 3 | 2023 | 1485 | 0.230 |
Why?
| | Protein Binding | 9 | 2018 | 2242 | 0.230 |
Why?
| | Arousal | 6 | 2002 | 160 | 0.220 |
Why?
| | Aminoquinolines | 1 | 2024 | 18 | 0.220 |
Why?
| | Antibodies | 6 | 2018 | 411 | 0.220 |
Why?
| | Spinal Nerve Roots | 3 | 2012 | 29 | 0.220 |
Why?
| | Analgesics | 5 | 2020 | 226 | 0.220 |
Why?
| | Cyclooxygenase 2 | 4 | 2019 | 176 | 0.220 |
Why?
| | Infrared Rays | 1 | 2024 | 26 | 0.220 |
Why?
| | Models, Immunological | 1 | 2005 | 101 | 0.220 |
Why?
| | Ligation | 3 | 2013 | 93 | 0.220 |
Why?
| | Nitric Oxide Synthase | 2 | 2004 | 242 | 0.220 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 5 | 2013 | 348 | 0.220 |
Why?
| | Administration, Cutaneous | 1 | 2024 | 129 | 0.220 |
Why?
| | Brain Mapping | 8 | 2018 | 532 | 0.220 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 4 | 2008 | 84 | 0.220 |
Why?
| | Injections, Intraventricular | 13 | 2015 | 55 | 0.210 |
Why?
| | Vesiculovirus | 1 | 2024 | 17 | 0.210 |
Why?
| | Models, Neurological | 2 | 2003 | 251 | 0.210 |
Why?
| | Central Nervous System Agents | 1 | 2003 | 7 | 0.210 |
Why?
| | Body Fluids | 1 | 2004 | 70 | 0.210 |
Why?
| | Cholecystokinin | 4 | 2000 | 15 | 0.210 |
Why?
| | Gap Junctions | 1 | 2004 | 63 | 0.210 |
Why?
| | Glial Fibrillary Acidic Protein | 8 | 2015 | 112 | 0.210 |
Why?
| | Transduction, Genetic | 1 | 2024 | 136 | 0.200 |
Why?
| | Norepinephrine | 5 | 2005 | 193 | 0.200 |
Why?
| | Neural Inhibition | 2 | 2010 | 177 | 0.200 |
Why?
| | Lumbosacral Region | 4 | 2013 | 62 | 0.200 |
Why?
| | Carrier Proteins | 5 | 2015 | 748 | 0.200 |
Why?
| | Central Nervous System Diseases | 2 | 2017 | 73 | 0.200 |
Why?
| | Antigens, CD | 4 | 2017 | 545 | 0.200 |
Why?
| | Mice, Knockout | 5 | 2021 | 3071 | 0.200 |
Why?
| | Animals, Genetically Modified | 1 | 2024 | 242 | 0.200 |
Why?
| | Adrenalectomy | 10 | 2014 | 70 | 0.200 |
Why?
| | Mifepristone | 6 | 2019 | 63 | 0.200 |
Why?
| | Freund's Adjuvant | 2 | 2013 | 17 | 0.190 |
Why?
| | Pituitary Gland | 6 | 2004 | 150 | 0.190 |
Why?
| | Enzyme Inhibitors | 6 | 2007 | 855 | 0.190 |
Why?
| | Receptors, Glucocorticoid | 5 | 2016 | 137 | 0.190 |
Why?
| | Learning | 7 | 2018 | 439 | 0.190 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 2 | 2015 | 209 | 0.190 |
Why?
| | Opioid-Related Disorders | 5 | 2017 | 564 | 0.190 |
Why?
| | Illness Behavior | 2 | 2014 | 8 | 0.190 |
Why?
| | Brain Chemistry | 3 | 2004 | 117 | 0.190 |
Why?
| | Cognitive Dysfunction | 2 | 2018 | 412 | 0.190 |
Why?
| | Fibroblast Growth Factor 2 | 3 | 2007 | 87 | 0.190 |
Why?
| | Myelin-Oligodendrocyte Glycoprotein | 2 | 2021 | 53 | 0.190 |
Why?
| | Gene Expression | 8 | 2020 | 1492 | 0.190 |
Why?
| | Random Allocation | 6 | 2016 | 367 | 0.180 |
Why?
| | Synaptic Transmission | 4 | 2010 | 295 | 0.180 |
Why?
| | Caspase 1 | 3 | 2020 | 147 | 0.180 |
Why?
| | Spleen | 7 | 2014 | 525 | 0.180 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 3 | 2016 | 281 | 0.180 |
Why?
| | Social Behavior | 8 | 2018 | 293 | 0.180 |
Why?
| | Cocaine-Related Disorders | 1 | 2023 | 136 | 0.180 |
Why?
| | Psychoneuroimmunology | 3 | 2002 | 10 | 0.180 |
Why?
| | Molecular Targeted Therapy | 2 | 2017 | 420 | 0.180 |
Why?
| | Affect | 3 | 2018 | 316 | 0.180 |
Why?
| | Immunity, Cellular | 2 | 2002 | 269 | 0.180 |
Why?
| | Indoles | 4 | 2013 | 478 | 0.180 |
Why?
| | GABA Antagonists | 4 | 2010 | 35 | 0.180 |
Why?
| | alpha7 Nicotinic Acetylcholine Receptor | 2 | 2012 | 98 | 0.170 |
Why?
| | Tail | 11 | 2007 | 29 | 0.170 |
Why?
| | Zymosan | 4 | 2005 | 66 | 0.170 |
Why?
| | Central Nervous System Depressants | 2 | 2014 | 89 | 0.170 |
Why?
| | Cell Communication | 3 | 2009 | 318 | 0.170 |
Why?
| | 8-Hydroxy-2-(di-n-propylamino)tetralin | 4 | 2009 | 8 | 0.170 |
Why?
| | Body Temperature | 5 | 2002 | 224 | 0.170 |
Why?
| | Fentanyl | 2 | 2019 | 120 | 0.170 |
Why?
| | Receptors, HIV | 3 | 2004 | 25 | 0.170 |
Why?
| | Touch | 3 | 2013 | 37 | 0.170 |
Why?
| | Neurogenesis | 1 | 2022 | 154 | 0.170 |
Why?
| | Receptors, Cytokine | 3 | 2004 | 36 | 0.170 |
Why?
| | Drug Interactions | 6 | 2008 | 406 | 0.170 |
Why?
| | Dexamethasone | 5 | 2012 | 380 | 0.160 |
Why?
| | Models, Molecular | 5 | 2012 | 1604 | 0.160 |
Why?
| | Thoracic Vertebrae | 2 | 2019 | 78 | 0.160 |
Why?
| | Convulsants | 4 | 1998 | 8 | 0.160 |
Why?
| | Specific Pathogen-Free Organisms | 5 | 2004 | 60 | 0.160 |
Why?
| | AIDS Dementia Complex | 1 | 2000 | 52 | 0.160 |
Why?
| | Dogs | 2 | 2020 | 427 | 0.160 |
Why?
| | Drug Synergism | 4 | 2015 | 375 | 0.160 |
Why?
| | Carbolines | 4 | 1998 | 35 | 0.160 |
Why?
| | Lithium Chloride | 3 | 1994 | 12 | 0.160 |
Why?
| | Skin | 1 | 2024 | 765 | 0.160 |
Why?
| | Lovastatin | 1 | 2019 | 38 | 0.150 |
Why?
| | Receptors, Corticotropin-Releasing Hormone | 4 | 2004 | 28 | 0.150 |
Why?
| | Hemocyanins | 8 | 2003 | 61 | 0.150 |
Why?
| | Thalamus | 2 | 2018 | 120 | 0.150 |
Why?
| | Microfilament Proteins | 3 | 2016 | 134 | 0.150 |
Why?
| | Antibody Formation | 6 | 2002 | 298 | 0.150 |
Why?
| | CLOCK Proteins | 1 | 2018 | 9 | 0.150 |
Why?
| | Diaphragm | 5 | 2001 | 45 | 0.150 |
Why?
| | Tumor Necrosis Factor Decoy Receptors | 3 | 2004 | 8 | 0.150 |
Why?
| | Purinergic P1 Receptor Agonists | 1 | 2018 | 8 | 0.150 |
Why?
| | Pituitary-Adrenal System | 5 | 2004 | 172 | 0.150 |
Why?
| | Receptors, Purinergic P1 | 1 | 2018 | 30 | 0.150 |
Why?
| | Motor Disorders | 1 | 2018 | 17 | 0.150 |
Why?
| | Immunization | 4 | 2018 | 406 | 0.150 |
Why?
| | Calcium-Binding Proteins | 3 | 2016 | 217 | 0.150 |
Why?
| | Medulla Oblongata | 2 | 2014 | 36 | 0.140 |
Why?
| | Mice, Inbred C57BL | 4 | 2021 | 5909 | 0.140 |
Why?
| | Restraint, Physical | 11 | 2007 | 73 | 0.140 |
Why?
| | Receptor, Serotonin, 5-HT1A | 2 | 2011 | 36 | 0.140 |
Why?
| | Recombinant Proteins | 8 | 2005 | 1363 | 0.140 |
Why?
| | Designer Drugs | 1 | 2018 | 6 | 0.140 |
Why?
| | Maze Learning | 2 | 2016 | 104 | 0.140 |
Why?
| | Molecular Docking Simulation | 2 | 2018 | 111 | 0.140 |
Why?
| | Gene Knockdown Techniques | 1 | 2019 | 333 | 0.140 |
Why?
| | Septal Nuclei | 2 | 2011 | 24 | 0.140 |
Why?
| | Abdomen | 1 | 1999 | 136 | 0.140 |
Why?
| | Sleep Disorders, Circadian Rhythm | 1 | 2018 | 52 | 0.140 |
Why?
| | Bacterial Vaccines | 1 | 2018 | 63 | 0.140 |
Why?
| | Body Weight | 4 | 2018 | 997 | 0.140 |
Why?
| | Probiotics | 1 | 2018 | 57 | 0.140 |
Why?
| | Transcortin | 4 | 1999 | 15 | 0.140 |
Why?
| | Cyclooxygenase 1 | 2 | 2008 | 28 | 0.140 |
Why?
| | Statistics, Nonparametric | 1 | 2018 | 434 | 0.140 |
Why?
| | Excitatory Amino Acid Antagonists | 1 | 2018 | 105 | 0.140 |
Why?
| | Muscimol | 7 | 2011 | 17 | 0.140 |
Why?
| | Receptors, Purinergic P2X7 | 1 | 2017 | 12 | 0.140 |
Why?
| | Methadone | 2 | 2010 | 110 | 0.140 |
Why?
| | Amphetamine | 3 | 2010 | 37 | 0.130 |
Why?
| | Brain Injuries | 2 | 2013 | 502 | 0.130 |
Why?
| | Nitrites | 2 | 2016 | 89 | 0.130 |
Why?
| | Biomarkers | 5 | 2012 | 4190 | 0.130 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2020 | 467 | 0.130 |
Why?
| | Acoustic Stimulation | 5 | 2011 | 325 | 0.130 |
Why?
| | Taste | 3 | 2008 | 232 | 0.130 |
Why?
| | Facial Nucleus | 1 | 2016 | 1 | 0.130 |
Why?
| | Rats, Inbred Strains | 7 | 2017 | 345 | 0.130 |
Why?
| | Toll-Like Receptor 5 | 1 | 2016 | 14 | 0.130 |
Why?
| | Dura Mater | 1 | 2017 | 34 | 0.130 |
Why?
| | Receptors, Purinergic P2X5 | 1 | 2016 | 4 | 0.130 |
Why?
| | Macrophage Activation | 1 | 2018 | 200 | 0.130 |
Why?
| | Activating Transcription Factor 3 | 1 | 2016 | 5 | 0.130 |
Why?
| | Habenula | 1 | 2016 | 13 | 0.130 |
Why?
| | p21-Activated Kinases | 1 | 2016 | 13 | 0.130 |
Why?
| | Spatial Memory | 1 | 2016 | 27 | 0.130 |
Why?
| | CX3C Chemokine Receptor 1 | 3 | 2004 | 19 | 0.130 |
Why?
| | Down-Regulation | 2 | 2017 | 641 | 0.130 |
Why?
| | Models, Biological | 3 | 2017 | 1828 | 0.120 |
Why?
| | Radiculopathy | 2 | 2014 | 39 | 0.120 |
Why?
| | Guanidines | 3 | 2003 | 44 | 0.120 |
Why?
| | Arrhythmias, Cardiac | 2 | 2018 | 337 | 0.120 |
Why?
| | Brain Ischemia | 2 | 2018 | 350 | 0.120 |
Why?
| | Neurogenic Inflammation | 1 | 2016 | 2 | 0.120 |
Why?
| | Hydrazones | 3 | 2003 | 26 | 0.120 |
Why?
| | Cell Count | 9 | 2009 | 326 | 0.120 |
Why?
| | Analgesics, Non-Narcotic | 1 | 1997 | 127 | 0.120 |
Why?
| | Flumazenil | 1 | 1995 | 9 | 0.120 |
Why?
| | Anilides | 3 | 2003 | 81 | 0.120 |
Why?
| | Nociception | 2 | 2015 | 17 | 0.120 |
Why?
| | Life Expectancy | 1 | 2016 | 71 | 0.120 |
Why?
| | Isomerism | 2 | 2018 | 56 | 0.120 |
Why?
| | Autoimmunity | 1 | 2021 | 908 | 0.120 |
Why?
| | Physical Conditioning, Animal | 3 | 2014 | 254 | 0.120 |
Why?
| | Antibodies, Neutralizing | 1 | 2018 | 323 | 0.110 |
Why?
| | Reflex, Abnormal | 1 | 2014 | 8 | 0.110 |
Why?
| | Excitatory Amino Acids | 1 | 1994 | 7 | 0.110 |
Why?
| | NG-Nitroarginine Methyl Ester | 2 | 2005 | 49 | 0.110 |
Why?
| | Picrotoxin | 5 | 2018 | 11 | 0.110 |
Why?
| | Polyethylene Glycols | 2 | 2010 | 641 | 0.110 |
Why?
| | Dopamine Plasma Membrane Transport Proteins | 1 | 2015 | 60 | 0.110 |
Why?
| | Drug Administration Routes | 2 | 2012 | 41 | 0.110 |
Why?
| | Mice, Inbred C3H | 1 | 2015 | 270 | 0.110 |
Why?
| | Body Temperature Regulation | 2 | 2009 | 102 | 0.110 |
Why?
| | Neuropeptides | 1 | 1994 | 77 | 0.110 |
Why?
| | Morphine Dependence | 2 | 2011 | 3 | 0.110 |
Why?
| | Memory, Long-Term | 3 | 2020 | 12 | 0.110 |
Why?
| | Circadian Clocks | 1 | 2014 | 58 | 0.110 |
Why?
| | Thiazolidinediones | 1 | 2015 | 138 | 0.110 |
Why?
| | Receptors, GABA-A | 1 | 1995 | 141 | 0.110 |
Why?
| | PPAR gamma | 1 | 2015 | 181 | 0.100 |
Why?
| | Host-Pathogen Interactions | 3 | 2012 | 372 | 0.100 |
Why?
| | Nervous System | 1 | 1994 | 68 | 0.100 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2014 | 76 | 0.100 |
Why?
| | Immunosuppressive Agents | 2 | 2013 | 855 | 0.100 |
Why?
| | Brain Stem | 2 | 2010 | 96 | 0.100 |
Why?
| | Leukocytes, Mononuclear | 1 | 2016 | 574 | 0.100 |
Why?
| | Glucose | 1 | 2019 | 1041 | 0.100 |
Why?
| | Phosphorylation | 3 | 2012 | 1774 | 0.100 |
Why?
| | B-Lymphocytes | 2 | 2012 | 859 | 0.100 |
Why?
| | Cell Death | 1 | 2015 | 387 | 0.100 |
Why?
| | Escherichia coli | 5 | 2016 | 838 | 0.100 |
Why?
| | Running | 2 | 2017 | 232 | 0.100 |
Why?
| | Pentamidine | 1 | 2012 | 3 | 0.100 |
Why?
| | Recovery of Function | 1 | 2017 | 684 | 0.100 |
Why?
| | Interleukins | 2 | 2006 | 251 | 0.100 |
Why?
| | Blood-Brain Barrier | 2 | 2009 | 145 | 0.100 |
Why?
| | Swimming | 1 | 2013 | 50 | 0.100 |
Why?
| | Viral Matrix Proteins | 1 | 2012 | 30 | 0.100 |
Why?
| | Heroin | 1 | 2013 | 31 | 0.100 |
Why?
| | Rats, Wistar | 4 | 2016 | 455 | 0.100 |
Why?
| | Serotonin Receptor Agonists | 4 | 2013 | 26 | 0.100 |
Why?
| | Interpersonal Relations | 1 | 2016 | 411 | 0.100 |
Why?
| | Rifampin | 1 | 2013 | 89 | 0.100 |
Why?
| | Adrenocorticotropic Hormone | 6 | 2004 | 148 | 0.100 |
Why?
| | Oncogene Proteins v-fos | 4 | 2015 | 11 | 0.090 |
Why?
| | Receptors, Cholecystokinin | 1 | 1992 | 9 | 0.090 |
Why?
| | Organ Culture Techniques | 2 | 2010 | 157 | 0.090 |
Why?
| | Lipopeptides | 1 | 2012 | 14 | 0.090 |
Why?
| | Somatostatin | 1 | 1992 | 58 | 0.090 |
Why?
| | Cytoskeletal Proteins | 2 | 2010 | 156 | 0.090 |
Why?
| | Cerebral Ventricles | 1 | 1992 | 55 | 0.090 |
Why?
| | Association Learning | 4 | 2007 | 63 | 0.090 |
Why?
| | DNA, Complementary | 2 | 2010 | 274 | 0.090 |
Why?
| | Structure-Activity Relationship | 3 | 2019 | 579 | 0.090 |
Why?
| | Tetracyclines | 1 | 2012 | 14 | 0.090 |
Why?
| | Behavior, Addictive | 1 | 2013 | 89 | 0.090 |
Why?
| | Cell Line, Transformed | 1 | 2012 | 145 | 0.090 |
Why?
| | Antigens | 3 | 2003 | 362 | 0.090 |
Why?
| | Gene Transfer Techniques | 2 | 2010 | 176 | 0.090 |
Why?
| | Tissue Distribution | 2 | 2016 | 330 | 0.090 |
Why?
| | Herpesvirus 4, Human | 1 | 2012 | 165 | 0.090 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2012 | 91 | 0.090 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2012 | 184 | 0.090 |
Why?
| | DNA Primers | 2 | 2010 | 510 | 0.090 |
Why?
| | Phenylurea Compounds | 1 | 1992 | 100 | 0.090 |
Why?
| | Mice, Inbred CBA | 1 | 2011 | 54 | 0.090 |
Why?
| | Macrophages, Peritoneal | 1 | 2011 | 97 | 0.090 |
Why?
| | Adaptor Proteins, Signal Transducing | 2 | 2017 | 439 | 0.090 |
Why?
| | Stroke | 2 | 2018 | 1158 | 0.090 |
Why?
| | Sensation | 1 | 1991 | 56 | 0.090 |
Why?
| | Vasodilation | 1 | 2014 | 516 | 0.090 |
Why?
| | Superoxides | 2 | 2022 | 217 | 0.090 |
Why?
| | Peptide Fragments | 3 | 2011 | 701 | 0.080 |
Why?
| | Rats, Inbred BN | 4 | 2012 | 56 | 0.080 |
Why?
| | Endocrine Glands | 1 | 1990 | 16 | 0.080 |
Why?
| | Phenylephrine | 1 | 1990 | 75 | 0.080 |
Why?
| | Heart Arrest | 1 | 2015 | 385 | 0.080 |
Why?
| | GABA Agonists | 4 | 2008 | 19 | 0.080 |
Why?
| | Drug Combinations | 2 | 2009 | 368 | 0.080 |
Why?
| | Benzylidene Compounds | 1 | 2010 | 20 | 0.080 |
Why?
| | Muscles | 1 | 1991 | 333 | 0.080 |
Why?
| | Prostaglandins | 2 | 2007 | 101 | 0.080 |
Why?
| | Sphingolipids | 1 | 2010 | 80 | 0.080 |
Why?
| | Food Preferences | 2 | 2008 | 124 | 0.080 |
Why?
| | Computational Biology | 2 | 2012 | 664 | 0.080 |
Why?
| | Mitochondria | 1 | 2016 | 979 | 0.080 |
Why?
| | Protein Interaction Mapping | 1 | 2010 | 103 | 0.080 |
Why?
| | Receptor, Serotonin, 5-HT2C | 1 | 2009 | 14 | 0.080 |
Why?
| | Anti-Infective Agents | 1 | 2012 | 239 | 0.080 |
Why?
| | Immunologic Factors | 1 | 2012 | 249 | 0.080 |
Why?
| | Receptors, Interleukin-1 Type I | 2 | 2011 | 25 | 0.080 |
Why?
| | Bradykinin | 1 | 2009 | 48 | 0.080 |
Why?
| | Stress Disorders, Traumatic | 1 | 2009 | 23 | 0.080 |
Why?
| | Histamine | 1 | 2009 | 59 | 0.080 |
Why?
| | Dimethyl Sulfoxide | 1 | 2009 | 41 | 0.080 |
Why?
| | Afferent Pathways | 3 | 2005 | 47 | 0.080 |
Why?
| | Hypnotics and Sedatives | 1 | 2012 | 214 | 0.080 |
Why?
| | Infusion Pumps | 1 | 2009 | 34 | 0.080 |
Why?
| | Motor Neurons | 1 | 2012 | 234 | 0.080 |
Why?
| | Amnesia, Retrograde | 2 | 2006 | 3 | 0.080 |
Why?
| | Toll-Like Receptor 9 | 1 | 2009 | 33 | 0.080 |
Why?
| | Injections, Intravenous | 3 | 1998 | 202 | 0.080 |
Why?
| | Eating | 3 | 2000 | 392 | 0.080 |
Why?
| | Antigens, Differentiation, Myelomonocytic | 1 | 2009 | 66 | 0.080 |
Why?
| | Lactams, Macrocyclic | 1 | 2009 | 50 | 0.080 |
Why?
| | Perception | 1 | 1992 | 378 | 0.080 |
Why?
| | Immunoglobulin M | 4 | 2001 | 287 | 0.080 |
Why?
| | Benzoquinones | 1 | 2009 | 48 | 0.080 |
Why?
| | Central Nervous System Infections | 1 | 2009 | 35 | 0.080 |
Why?
| | CpG Islands | 1 | 2009 | 165 | 0.070 |
Why?
| | Disease Susceptibility | 1 | 2011 | 353 | 0.070 |
Why?
| | Neoplasms | 2 | 2010 | 2747 | 0.070 |
Why?
| | Anxiety Disorders | 1 | 2012 | 380 | 0.070 |
Why?
| | High-Throughput Screening Assays | 1 | 2010 | 157 | 0.070 |
Why?
| | Spatial Behavior | 1 | 2008 | 26 | 0.070 |
Why?
| | Cognition Disorders | 1 | 2012 | 518 | 0.070 |
Why?
| | Age Factors | 7 | 2010 | 3294 | 0.070 |
Why?
| | RAW 264.7 Cells | 2 | 2019 | 49 | 0.070 |
Why?
| | Sex Factors | 2 | 2012 | 2063 | 0.070 |
Why?
| | Ligands | 1 | 2010 | 667 | 0.070 |
Why?
| | beta-Adrenergic Receptor Kinases | 1 | 2007 | 4 | 0.070 |
Why?
| | RNA, Antisense | 1 | 2007 | 17 | 0.070 |
Why?
| | Drugs, Investigational | 1 | 2007 | 32 | 0.070 |
Why?
| | Safety | 3 | 2008 | 356 | 0.070 |
Why?
| | Mice, Transgenic | 1 | 2012 | 2184 | 0.060 |
Why?
| | Immune Tolerance | 1 | 2009 | 376 | 0.060 |
Why?
| | Mental Disorders | 1 | 2016 | 1130 | 0.060 |
Why?
| | Cholesterol | 2 | 2003 | 405 | 0.060 |
Why?
| | Foreign-Body Reaction | 1 | 2007 | 33 | 0.060 |
Why?
| | GABA-A Receptor Agonists | 3 | 2011 | 17 | 0.060 |
Why?
| | Receptors, Serotonin | 2 | 1997 | 35 | 0.060 |
Why?
| | Stereoisomerism | 2 | 2019 | 107 | 0.060 |
Why?
| | Mutation | 2 | 2015 | 4015 | 0.060 |
Why?
| | Evidence-Based Medicine | 1 | 2010 | 750 | 0.060 |
Why?
| | Injections, Intramuscular | 1 | 2006 | 135 | 0.060 |
Why?
| | Genes, MHC Class II | 1 | 2006 | 75 | 0.060 |
Why?
| | Enzyme Activation | 2 | 2005 | 811 | 0.060 |
Why?
| | Oxidative Stress | 1 | 2013 | 1334 | 0.060 |
Why?
| | Antibodies, Blocking | 1 | 2005 | 36 | 0.060 |
Why?
| | Sodium Chloride | 1 | 2006 | 140 | 0.060 |
Why?
| | Peptides | 2 | 2009 | 979 | 0.060 |
Why?
| | Transcriptome | 1 | 2012 | 1014 | 0.060 |
Why?
| | Centrifugation | 1 | 2005 | 27 | 0.060 |
Why?
| | Electric Stimulation | 4 | 2011 | 281 | 0.060 |
Why?
| | Histocompatibility Antigens | 1 | 2006 | 108 | 0.060 |
Why?
| | Hypoglycemic Agents | 1 | 2015 | 1374 | 0.060 |
Why?
| | Caspase Inhibitors | 1 | 2005 | 81 | 0.060 |
Why?
| | Reinforcement Schedule | 3 | 2017 | 31 | 0.060 |
Why?
| | Blotting, Western | 3 | 2013 | 1234 | 0.060 |
Why?
| | Cell Survival | 3 | 2019 | 1134 | 0.060 |
Why?
| | Complement C5a | 1 | 2005 | 71 | 0.060 |
Why?
| | Hormone Antagonists | 3 | 2016 | 34 | 0.060 |
Why?
| | Postoperative Complications | 2 | 2012 | 2821 | 0.060 |
Why?
| | Complement C3a | 1 | 2005 | 42 | 0.060 |
Why?
| | Electric Countershock | 2 | 1984 | 107 | 0.060 |
Why?
| | Epilepsy | 1 | 2009 | 349 | 0.060 |
Why?
| | Adrenal Glands | 2 | 2018 | 80 | 0.060 |
Why?
| | Carbenoxolone | 1 | 2004 | 1 | 0.060 |
Why?
| | Glycyrrhizic Acid | 1 | 2004 | 3 | 0.060 |
Why?
| | Computer Simulation | 1 | 2009 | 1015 | 0.060 |
Why?
| | Anti-Ulcer Agents | 1 | 2004 | 15 | 0.060 |
Why?
| | Nerve Compression Syndromes | 1 | 2004 | 22 | 0.060 |
Why?
| | In Vitro Techniques | 1 | 2006 | 1094 | 0.060 |
Why?
| | Stress, Mechanical | 1 | 2007 | 489 | 0.050 |
Why?
| | Nitric Oxide Synthase Type I | 1 | 2004 | 29 | 0.050 |
Why?
| | Clinical Trials as Topic | 1 | 2009 | 1057 | 0.050 |
Why?
| | Cell Separation | 1 | 2005 | 317 | 0.050 |
Why?
| | Receptors, Adrenergic, alpha-1 | 1 | 2004 | 45 | 0.050 |
Why?
| | N-Methylaspartate | 1 | 2004 | 43 | 0.050 |
Why?
| | Catalase | 1 | 2004 | 134 | 0.050 |
Why?
| | Adenoviridae | 1 | 2005 | 201 | 0.050 |
Why?
| | Hypothermia | 1 | 2004 | 45 | 0.050 |
Why?
| | Binding Sites | 2 | 2018 | 1316 | 0.050 |
Why?
| | Peripheral Nervous System | 1 | 2003 | 20 | 0.050 |
Why?
| | Receptors, Opioid, kappa | 2 | 1994 | 10 | 0.050 |
Why?
| | Sample Size | 1 | 2004 | 128 | 0.050 |
Why?
| | Complement Membrane Attack Complex | 1 | 2023 | 38 | 0.050 |
Why?
| | Hydrocortisone | 5 | 2009 | 318 | 0.050 |
Why?
| | Histocompatibility Antigens Class II | 2 | 2010 | 369 | 0.050 |
Why?
| | Viral Envelope Proteins | 1 | 2024 | 97 | 0.050 |
Why?
| | Mental Recall | 2 | 1995 | 210 | 0.050 |
Why?
| | Lymph Nodes | 3 | 2001 | 502 | 0.050 |
Why?
| | Aconitate Hydratase | 1 | 2003 | 17 | 0.050 |
Why?
| | Chromatography, High Pressure Liquid | 4 | 2009 | 595 | 0.050 |
Why?
| | Pressure | 1 | 2004 | 230 | 0.050 |
Why?
| | Immunoglobulin G | 4 | 2002 | 900 | 0.050 |
Why?
| | Neck | 2 | 2001 | 105 | 0.050 |
Why?
| | Cell Culture Techniques | 1 | 2005 | 368 | 0.050 |
Why?
| | Adult | 4 | 2022 | 39391 | 0.050 |
Why?
| | Adrenergic alpha-1 Receptor Antagonists | 1 | 2002 | 17 | 0.050 |
Why?
| | Adrenergic alpha-Antagonists | 1 | 2002 | 34 | 0.050 |
Why?
| | Immobility Response, Tonic | 2 | 2013 | 5 | 0.050 |
Why?
| | Peripheral Nerves | 1 | 2003 | 71 | 0.050 |
Why?
| | Reflex | 2 | 1994 | 70 | 0.050 |
Why?
| | Social Isolation | 1 | 2003 | 66 | 0.050 |
Why?
| | Receptors, Cell Surface | 1 | 2004 | 398 | 0.050 |
Why?
| | Peroxynitrous Acid | 1 | 2022 | 13 | 0.050 |
Why?
| | Psychomotor Performance | 3 | 2015 | 329 | 0.050 |
Why?
| | Glycoproteins | 1 | 2024 | 358 | 0.050 |
Why?
| | Superoxide Dismutase | 1 | 2004 | 352 | 0.050 |
Why?
| | Death, Sudden | 1 | 1982 | 23 | 0.050 |
Why?
| | NADPH Oxidase 2 | 1 | 2022 | 41 | 0.050 |
Why?
| | Antioxidants | 2 | 2022 | 599 | 0.050 |
Why?
| | Nodose Ganglion | 2 | 1998 | 5 | 0.050 |
Why?
| | Lumbar Vertebrae | 1 | 2004 | 251 | 0.050 |
Why?
| | Extracellular Vesicles | 1 | 2024 | 153 | 0.050 |
Why?
| | Myelin Sheath | 1 | 2023 | 165 | 0.050 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2013 | 346 | 0.050 |
Why?
| | Evoked Potentials, Auditory | 2 | 2011 | 181 | 0.040 |
Why?
| | Stem Cells | 1 | 2006 | 603 | 0.040 |
Why?
| | Ventricular Fibrillation | 1 | 1982 | 62 | 0.040 |
Why?
| | T-Lymphocyte Subsets | 2 | 1995 | 415 | 0.040 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2022 | 174 | 0.040 |
Why?
| | Cell Line, Tumor | 2 | 2024 | 3495 | 0.040 |
Why?
| | Membrane Glycoproteins | 1 | 2024 | 502 | 0.040 |
Why?
| | Interferon-gamma | 4 | 2001 | 792 | 0.040 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2003 | 317 | 0.040 |
Why?
| | Viral Proteins | 1 | 2024 | 369 | 0.040 |
Why?
| | Reproducibility of Results | 2 | 2012 | 3356 | 0.040 |
Why?
| | Acute Disease | 2 | 2001 | 1010 | 0.040 |
Why?
| | NF-E2-Related Factor 2 | 1 | 2022 | 94 | 0.040 |
Why?
| | Epinephrine | 3 | 2002 | 148 | 0.040 |
Why?
| | Protein Conformation | 2 | 2018 | 941 | 0.040 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 2 | 2012 | 336 | 0.040 |
Why?
| | Injections | 2 | 2013 | 191 | 0.040 |
Why?
| | Aminopyridines | 2 | 2013 | 109 | 0.040 |
Why?
| | Phosphate-Binding Proteins | 1 | 2020 | 6 | 0.040 |
Why?
| | Organ Size | 1 | 2001 | 481 | 0.040 |
Why?
| | Rodentia | 1 | 2020 | 59 | 0.040 |
Why?
| | Evoked Potentials, Somatosensory | 2 | 2011 | 39 | 0.040 |
Why?
| | Crisis Intervention | 1 | 2020 | 33 | 0.040 |
Why?
| | Amino Acid Sequence | 2 | 2016 | 2158 | 0.040 |
Why?
| | Depression | 2 | 2008 | 1508 | 0.040 |
Why?
| | Adjuvants, Immunologic | 2 | 2003 | 240 | 0.040 |
Why?
| | Receptors, Mineralocorticoid | 1 | 1999 | 11 | 0.040 |
Why?
| | Alzheimer Disease | 2 | 2020 | 595 | 0.040 |
Why?
| | Peritoneum | 1 | 2000 | 47 | 0.040 |
Why?
| | Subarachnoid Space | 1 | 1999 | 9 | 0.040 |
Why?
| | Therapeutic Irrigation | 1 | 2000 | 79 | 0.040 |
Why?
| | Urocortins | 3 | 2004 | 23 | 0.040 |
Why?
| | Paresis | 1 | 1999 | 31 | 0.040 |
Why?
| | Coronary Disease | 1 | 1982 | 371 | 0.040 |
Why?
| | Opioid Peptides | 1 | 1999 | 9 | 0.040 |
Why?
| | Motor Skills Disorders | 1 | 1999 | 29 | 0.040 |
Why?
| | Pyrimidines | 2 | 2003 | 512 | 0.040 |
Why?
| | Fluorescent Dyes | 2 | 2012 | 324 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2004 | 1977 | 0.040 |
Why?
| | alpha-MSH | 1 | 1998 | 5 | 0.040 |
Why?
| | Immunity | 1 | 2000 | 140 | 0.040 |
Why?
| | RNA, Double-Stranded | 1 | 2019 | 59 | 0.040 |
Why?
| | Anti-Bacterial Agents | 2 | 2008 | 1866 | 0.040 |
Why?
| | Primary Cell Culture | 1 | 2019 | 171 | 0.040 |
Why?
| | Acute-Phase Reaction | 1 | 1998 | 39 | 0.040 |
Why?
| | Cerebellum | 1 | 2000 | 218 | 0.040 |
Why?
| | Glossopharyngeal Nerve | 1 | 1998 | 11 | 0.040 |
Why?
| | Immunologic Deficiency Syndromes | 2 | 2001 | 72 | 0.040 |
Why?
| | Optical Fibers | 1 | 2018 | 17 | 0.040 |
Why?
| | Limbic Lobe | 1 | 2018 | 3 | 0.040 |
Why?
| | Neuroanatomical Tract-Tracing Techniques | 1 | 2018 | 5 | 0.040 |
Why?
| | Stilbamidines | 1 | 2018 | 10 | 0.040 |
Why?
| | Injections, Epidural | 1 | 1998 | 28 | 0.040 |
Why?
| | Protein Structure, Secondary | 1 | 2019 | 368 | 0.040 |
Why?
| | Vaccines, Inactivated | 1 | 2018 | 68 | 0.040 |
Why?
| | Fluorescent Antibody Technique | 1 | 1999 | 386 | 0.040 |
Why?
| | Bromodeoxyuridine | 2 | 2009 | 80 | 0.030 |
Why?
| | Administration, Intranasal | 1 | 2018 | 92 | 0.030 |
Why?
| | Memory, Short-Term | 1 | 2020 | 267 | 0.030 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2005 | 663 | 0.030 |
Why?
| | Cell Proliferation | 3 | 2012 | 2506 | 0.030 |
Why?
| | Isonicotinic Acids | 1 | 1997 | 2 | 0.030 |
Why?
| | Pyrroles | 1 | 1999 | 210 | 0.030 |
Why?
| | Receptors, GABA | 1 | 1997 | 14 | 0.030 |
Why?
| | Thermosensing | 2 | 1997 | 12 | 0.030 |
Why?
| | Sucrose | 2 | 2008 | 111 | 0.030 |
Why?
| | Oxytocics | 1 | 1997 | 15 | 0.030 |
Why?
| | Amnesia, Anterograde | 2 | 2008 | 4 | 0.030 |
Why?
| | Biguanides | 1 | 1997 | 10 | 0.030 |
Why?
| | Immunoassay | 1 | 2018 | 113 | 0.030 |
Why?
| | Baclofen | 1 | 1997 | 20 | 0.030 |
Why?
| | Mannose | 1 | 2017 | 24 | 0.030 |
Why?
| | Analgesia, Epidural | 1 | 1997 | 40 | 0.030 |
Why?
| | Skin Temperature | 2 | 1994 | 31 | 0.030 |
Why?
| | Histocytochemistry | 1 | 1997 | 80 | 0.030 |
Why?
| | Phosphopyruvate Hydratase | 2 | 2007 | 27 | 0.030 |
Why?
| | Basolateral Nuclear Complex | 1 | 2016 | 11 | 0.030 |
Why?
| | RNA, Small Interfering | 1 | 2019 | 627 | 0.030 |
Why?
| | Transcriptional Activation | 1 | 1999 | 378 | 0.030 |
Why?
| | Drug Evaluation, Preclinical | 1 | 1997 | 196 | 0.030 |
Why?
| | Extracellular Space | 2 | 2009 | 129 | 0.030 |
Why?
| | Nerve Net | 1 | 2000 | 281 | 0.030 |
Why?
| | Jurkat Cells | 1 | 2016 | 138 | 0.030 |
Why?
| | Period Circadian Proteins | 1 | 2016 | 33 | 0.030 |
Why?
| | Receptors, Adrenergic, beta | 1 | 1996 | 69 | 0.030 |
Why?
| | Immunoglobulins | 1 | 1996 | 168 | 0.030 |
Why?
| | Psychological Tests | 1 | 2016 | 136 | 0.030 |
Why?
| | Anesthetics, Dissociative | 1 | 2016 | 35 | 0.030 |
Why?
| | Dentate Gyrus | 2 | 2006 | 39 | 0.030 |
Why?
| | Hypercholesterolemia | 1 | 1996 | 101 | 0.030 |
Why?
| | Dysgammaglobulinemia | 1 | 1995 | 2 | 0.030 |
Why?
| | IgG Deficiency | 1 | 1995 | 7 | 0.030 |
Why?
| | Leukocytes | 2 | 2011 | 309 | 0.030 |
Why?
| | Saccharin | 1 | 1995 | 8 | 0.030 |
Why?
| | Optogenetics | 1 | 2016 | 110 | 0.030 |
Why?
| | Animal Diseases | 1 | 2015 | 8 | 0.030 |
Why?
| | Leukocyte Common Antigens | 1 | 1995 | 90 | 0.030 |
Why?
| | 11-beta-Hydroxysteroid Dehydrogenase Type 1 | 1 | 2014 | 9 | 0.030 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 1995 | 51 | 0.030 |
Why?
| | Capsaicin | 1 | 2015 | 30 | 0.030 |
Why?
| | 6-Cyano-7-nitroquinoxaline-2,3-dione | 1 | 1994 | 6 | 0.030 |
Why?
| | Chlorisondamine | 1 | 1994 | 3 | 0.030 |
Why?
| | Adrenal Medulla | 1 | 1994 | 9 | 0.030 |
Why?
| | Staphylococcal Infections | 1 | 1999 | 392 | 0.030 |
Why?
| | CD4 Antigens | 1 | 1995 | 141 | 0.030 |
Why?
| | Blood Proteins | 1 | 1997 | 250 | 0.030 |
Why?
| | Substance P | 1 | 1994 | 37 | 0.030 |
Why?
| | Enkephalin, Ala(2)-MePhe(4)-Gly(5)- | 1 | 2014 | 11 | 0.030 |
Why?
| | Weight Gain | 1 | 2018 | 539 | 0.030 |
Why?
| | Monitoring, Physiologic | 2 | 1990 | 285 | 0.030 |
Why?
| | In Situ Hybridization | 2 | 2005 | 320 | 0.030 |
Why?
| | Ganglionectomy | 1 | 1994 | 2 | 0.030 |
Why?
| | Kupffer Cells | 1 | 1994 | 49 | 0.030 |
Why?
| | Decerebrate State | 1 | 1994 | 3 | 0.030 |
Why?
| | Biphenyl Compounds | 1 | 1994 | 71 | 0.030 |
Why?
| | Area Under Curve | 1 | 2015 | 324 | 0.030 |
Why?
| | Ganglia, Sympathetic | 1 | 1994 | 14 | 0.030 |
Why?
| | Monocytes | 1 | 1997 | 579 | 0.030 |
Why?
| | Auditory Cortex | 1 | 1994 | 43 | 0.030 |
Why?
| | Valine | 1 | 2014 | 77 | 0.030 |
Why?
| | Basal Ganglia | 1 | 1994 | 57 | 0.030 |
Why?
| | Catalysis | 1 | 2014 | 320 | 0.030 |
Why?
| | Adiposity | 1 | 2018 | 521 | 0.030 |
Why?
| | Antidepressive Agents | 1 | 2016 | 254 | 0.030 |
Why?
| | Respiration | 1 | 2014 | 210 | 0.030 |
Why?
| | Biological Transport | 1 | 1995 | 410 | 0.030 |
Why?
| | Treatment Outcome | 3 | 2016 | 11181 | 0.030 |
Why?
| | Weight Loss | 2 | 2009 | 791 | 0.030 |
Why?
| | Pregnancy | 3 | 2017 | 7092 | 0.020 |
Why?
| | Infusion Pumps, Implantable | 1 | 2013 | 26 | 0.020 |
Why?
| | Receptors, Opioid, delta | 1 | 1992 | 10 | 0.020 |
Why?
| | Benzodiazepinones | 1 | 1992 | 18 | 0.020 |
Why?
| | Anesthetics | 1 | 1993 | 98 | 0.020 |
Why?
| | Receptors, IgE | 1 | 2012 | 44 | 0.020 |
Why?
| | Spodoptera | 1 | 2012 | 40 | 0.020 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 1 | 2014 | 228 | 0.020 |
Why?
| | MAP Kinase Kinase 4 | 1 | 2012 | 24 | 0.020 |
Why?
| | Receptors, IgG | 1 | 2012 | 77 | 0.020 |
Why?
| | NF-KappaB Inhibitor alpha | 1 | 2012 | 50 | 0.020 |
Why?
| | Phosphatidylcholines | 1 | 2013 | 136 | 0.020 |
Why?
| | Virus Activation | 1 | 2012 | 86 | 0.020 |
Why?
| | Gliosarcoma | 1 | 1992 | 8 | 0.020 |
Why?
| | Biological Assay | 1 | 2012 | 131 | 0.020 |
Why?
| | Lymphocyte Transfusion | 1 | 1992 | 21 | 0.020 |
Why?
| | Biophysics | 1 | 2012 | 74 | 0.020 |
Why?
| | Calcitonin Gene-Related Peptide | 1 | 2012 | 38 | 0.020 |
Why?
| | I-kappa B Proteins | 1 | 2012 | 76 | 0.020 |
Why?
| | Dimerization | 1 | 2012 | 196 | 0.020 |
Why?
| | Kinetics | 2 | 2006 | 1655 | 0.020 |
Why?
| | Oxidation-Reduction | 1 | 2015 | 1087 | 0.020 |
Why?
| | Azoles | 1 | 2011 | 4 | 0.020 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2012 | 132 | 0.020 |
Why?
| | Nitrobenzenes | 1 | 2011 | 18 | 0.020 |
Why?
| | Foot | 1 | 1992 | 100 | 0.020 |
Why?
| | Tetrodotoxin | 1 | 2011 | 41 | 0.020 |
Why?
| | Physical Exertion | 1 | 1992 | 209 | 0.020 |
Why?
| | Protein Multimerization | 1 | 2012 | 194 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2019 | 2006 | 0.020 |
Why?
| | T-Cell Antigen Receptor Specificity | 1 | 2011 | 51 | 0.020 |
Why?
| | Molecular Mimicry | 1 | 2011 | 42 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2012 | 302 | 0.020 |
Why?
| | Biotin | 1 | 2011 | 26 | 0.020 |
Why?
| | Rotarod Performance Test | 1 | 2011 | 16 | 0.020 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2015 | 328 | 0.020 |
Why?
| | Reflex, Righting | 1 | 2011 | 15 | 0.020 |
Why?
| | Pyramidal Tracts | 1 | 2011 | 31 | 0.020 |
Why?
| | Electrophysiology | 1 | 2011 | 217 | 0.020 |
Why?
| | Dextrans | 1 | 2011 | 85 | 0.020 |
Why?
| | Arginine Vasopressin | 1 | 1990 | 43 | 0.020 |
Why?
| | Spectrometry, Fluorescence | 1 | 2011 | 167 | 0.020 |
Why?
| | Sphingosine | 1 | 2010 | 45 | 0.020 |
Why?
| | Vasopressins | 1 | 1990 | 60 | 0.020 |
Why?
| | Interleukin-2 | 1 | 1992 | 456 | 0.020 |
Why?
| | Lysophospholipids | 1 | 2010 | 80 | 0.020 |
Why?
| | RNA Interference | 1 | 2012 | 469 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2012 | 859 | 0.020 |
Why?
| | Polyglycolic Acid | 1 | 2010 | 44 | 0.020 |
Why?
| | PC12 Cells | 1 | 2009 | 40 | 0.020 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2010 | 145 | 0.020 |
Why?
| | Dominance-Subordination | 1 | 2009 | 16 | 0.020 |
Why?
| | Serotonin Antagonists | 1 | 2009 | 31 | 0.020 |
Why?
| | Antimetabolites | 1 | 2009 | 21 | 0.020 |
Why?
| | Genes, fos | 1 | 2009 | 37 | 0.020 |
Why?
| | Esters | 1 | 2009 | 77 | 0.020 |
Why?
| | Temperature | 1 | 1992 | 669 | 0.020 |
Why?
| | Drinking | 2 | 1999 | 42 | 0.020 |
Why?
| | Adaptation, Physiological | 2 | 2003 | 562 | 0.020 |
Why?
| | Vaccination | 1 | 2018 | 1472 | 0.020 |
Why?
| | Myelin-Associated Glycoprotein | 1 | 2008 | 7 | 0.020 |
Why?
| | Aldehydes | 1 | 2009 | 146 | 0.020 |
Why?
| | Biological Products | 1 | 2012 | 239 | 0.020 |
Why?
| | Electromyography | 1 | 1991 | 411 | 0.020 |
Why?
| | Microscopy, Confocal | 1 | 2009 | 324 | 0.020 |
Why?
| | Myelin Proteins | 1 | 2008 | 45 | 0.020 |
Why?
| | Particle Size | 1 | 2010 | 404 | 0.020 |
Why?
| | GABA-A Receptor Antagonists | 1 | 2008 | 19 | 0.020 |
Why?
| | Lactic Acid | 1 | 2010 | 303 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 1995 | 1115 | 0.020 |
Why?
| | Action Potentials | 1 | 2011 | 499 | 0.020 |
Why?
| | Exercise Test | 1 | 2011 | 624 | 0.020 |
Why?
| | Endothelium, Vascular | 1 | 1995 | 951 | 0.020 |
Why?
| | Parietal Lobe | 1 | 2008 | 60 | 0.020 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2009 | 138 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2011 | 825 | 0.020 |
Why?
| | Immunotherapy, Adoptive | 1 | 1992 | 360 | 0.020 |
Why?
| | Naproxen | 1 | 2007 | 17 | 0.020 |
Why?
| | G-Protein-Coupled Receptor Kinase 2 | 1 | 2007 | 9 | 0.020 |
Why?
| | Bronchodilator Agents | 1 | 2008 | 196 | 0.020 |
Why?
| | Anticonvulsants | 1 | 2009 | 226 | 0.020 |
Why?
| | Immunologic Memory | 1 | 2009 | 360 | 0.020 |
Why?
| | Endotoxemia | 1 | 2007 | 87 | 0.020 |
Why?
| | Mesentery | 2 | 1998 | 45 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2011 | 2929 | 0.020 |
Why?
| | Heart Rate | 1 | 1990 | 821 | 0.020 |
Why?
| | Gyrus Cinguli | 1 | 2006 | 95 | 0.020 |
Why?
| | Mass Spectrometry | 1 | 2009 | 740 | 0.020 |
Why?
| | Bacterial Proteins | 1 | 2012 | 912 | 0.020 |
Why?
| | Thiocarbamates | 1 | 2005 | 6 | 0.020 |
Why?
| | Microtubule-Associated Proteins | 1 | 2007 | 198 | 0.010 |
Why?
| | Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2005 | 50 | 0.010 |
Why?
| | Locus Coeruleus | 1 | 2005 | 22 | 0.010 |
Why?
| | Estrous Cycle | 1 | 2005 | 20 | 0.010 |
Why?
| | Tyrosine 3-Monooxygenase | 1 | 2005 | 73 | 0.010 |
Why?
| | Phenotype | 2 | 2009 | 3177 | 0.010 |
Why?
| | 5,7-Dihydroxytryptamine | 1 | 2004 | 3 | 0.010 |
Why?
| | Pro-Opiomelanocortin | 1 | 2004 | 21 | 0.010 |
Why?
| | Motor Cortex | 1 | 2005 | 63 | 0.010 |
Why?
| | Aminoglutethimide | 1 | 2004 | 5 | 0.010 |
Why?
| | Metyrapone | 1 | 2004 | 5 | 0.010 |
Why?
| | Proline | 1 | 2005 | 80 | 0.010 |
Why?
| | Serotonin Agents | 1 | 2004 | 9 | 0.010 |
Why?
| | Reptilian Proteins | 1 | 2004 | 3 | 0.010 |
Why?
| | Rats, Mutant Strains | 1 | 2004 | 24 | 0.010 |
Why?
| | Group II Phospholipases A2 | 1 | 2004 | 10 | 0.010 |
Why?
| | Receptors, Leptin | 1 | 2004 | 25 | 0.010 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2009 | 774 | 0.010 |
Why?
| | Electrochemistry | 1 | 2004 | 76 | 0.010 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 2004 | 83 | 0.010 |
Why?
| | Transcription Factors | 1 | 2012 | 1712 | 0.010 |
Why?
| | Catecholamines | 1 | 2004 | 93 | 0.010 |
Why?
| | HIV Infections | 1 | 1999 | 3022 | 0.010 |
Why?
| | Nanoparticles | 1 | 2010 | 484 | 0.010 |
Why?
| | Concanavalin A | 1 | 2003 | 75 | 0.010 |
Why?
| | Serotonin 5-HT1 Receptor Antagonists | 1 | 2003 | 2 | 0.010 |
Why?
| | Cholesterol, VLDL | 1 | 2003 | 5 | 0.010 |
Why?
| | Electrolysis | 1 | 2003 | 2 | 0.010 |
Why?
| | Immobilization | 1 | 2003 | 46 | 0.010 |
Why?
| | Blood Pressure | 1 | 1990 | 1748 | 0.010 |
Why?
| | Sepsis | 1 | 2010 | 621 | 0.010 |
Why?
| | Sleep | 1 | 2011 | 885 | 0.010 |
Why?
| | Apoptosis | 1 | 2012 | 2576 | 0.010 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2011 | 2135 | 0.010 |
Why?
| | Oxathiins | 1 | 2002 | 1 | 0.010 |
Why?
| | Cholesterol, HDL | 1 | 2003 | 196 | 0.010 |
Why?
| | Drug Resistance | 1 | 2003 | 150 | 0.010 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2004 | 198 | 0.010 |
Why?
| | Prostheses and Implants | 1 | 1984 | 144 | 0.010 |
Why?
| | Brain Neoplasms | 1 | 1992 | 1305 | 0.010 |
Why?
| | Physical Examination | 1 | 2003 | 242 | 0.010 |
Why?
| | Aniline Compounds | 1 | 2003 | 120 | 0.010 |
Why?
| | Neuropsychological Tests | 1 | 2006 | 1093 | 0.010 |
Why?
| | Cell Division | 1 | 2003 | 798 | 0.010 |
Why?
| | Wallerian Degeneration | 1 | 2001 | 3 | 0.010 |
Why?
| | Gelatin Sponge, Absorbable | 1 | 2001 | 5 | 0.010 |
Why?
| | Tachycardia | 1 | 1982 | 55 | 0.010 |
Why?
| | Dopamine Uptake Inhibitors | 1 | 2002 | 60 | 0.010 |
Why?
| | Epitopes | 1 | 2003 | 477 | 0.010 |
Why?
| | Muscle Denervation | 1 | 2001 | 9 | 0.010 |
Why?
| | Cholesterol, LDL | 1 | 2003 | 361 | 0.010 |
Why?
| | Lymphocyte Count | 1 | 2001 | 167 | 0.010 |
Why?
| | Luminescent Measurements | 1 | 2001 | 74 | 0.010 |
Why?
| | Immunoglobulin Isotypes | 1 | 2001 | 36 | 0.010 |
Why?
| | Emotions | 1 | 2006 | 579 | 0.010 |
Why?
| | Organ Specificity | 1 | 2002 | 312 | 0.010 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2006 | 876 | 0.010 |
Why?
| | Diagnostic Imaging | 1 | 2004 | 327 | 0.010 |
Why?
| | Spironolactone | 1 | 2001 | 34 | 0.010 |
Why?
| | Hypertrophy | 1 | 2001 | 136 | 0.010 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2005 | 408 | 0.010 |
Why?
| | Long-Term Potentiation | 1 | 2002 | 200 | 0.010 |
Why?
| | Thymus Gland | 1 | 2001 | 319 | 0.010 |
Why?
| | Gene Expression Profiling | 1 | 2006 | 1771 | 0.010 |
Why?
| | Periaqueductal Gray | 1 | 1999 | 38 | 0.010 |
Why?
| | Peritoneal Cavity | 1 | 1998 | 31 | 0.010 |
Why?
| | Prognosis | 1 | 2007 | 4080 | 0.010 |
Why?
| | Administration, Oral | 1 | 2001 | 803 | 0.010 |
Why?
| | Rats, Long-Evans | 1 | 1998 | 122 | 0.010 |
Why?
| | Hydroxyindoleacetic Acid | 1 | 1998 | 26 | 0.010 |
Why?
| | CD4 Lymphocyte Count | 1 | 1998 | 284 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2007 | 5212 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2001 | 1197 | 0.010 |
Why?
| | Butoxamine | 1 | 1996 | 1 | 0.010 |
Why?
| | Atenolol | 1 | 1996 | 8 | 0.010 |
Why?
| | Receptors, Adrenergic, beta-1 | 1 | 1996 | 22 | 0.010 |
Why?
| | Receptors, Adrenergic, beta-2 | 1 | 1996 | 33 | 0.010 |
Why?
| | Propranolol | 1 | 1996 | 45 | 0.010 |
Why?
| | Fatty Acids, Nonesterified | 1 | 1996 | 158 | 0.010 |
Why?
| | Diazepam | 1 | 1995 | 35 | 0.010 |
Why?
| | Anti-Anxiety Agents | 1 | 1995 | 43 | 0.010 |
Why?
| | Adrenal Cortex Hormones | 1 | 1999 | 501 | 0.010 |
Why?
| | Adrenergic beta-Antagonists | 1 | 1996 | 228 | 0.010 |
Why?
| | Electrodes, Implanted | 1 | 1995 | 113 | 0.010 |
Why?
| | Nylons | 1 | 1995 | 22 | 0.010 |
Why?
| | Cytological Techniques | 1 | 1995 | 28 | 0.010 |
Why?
| | Prospective Studies | 1 | 2007 | 7777 | 0.010 |
Why?
| | Jugular Veins | 1 | 1994 | 42 | 0.010 |
Why?
| | Horseradish Peroxidase | 1 | 1994 | 27 | 0.010 |
Why?
| | Methoxyflurane | 1 | 1993 | 2 | 0.010 |
Why?
| | Chloral Hydrate | 1 | 1993 | 3 | 0.010 |
Why?
| | Halothane | 1 | 1993 | 7 | 0.010 |
Why?
| | Pentobarbital | 1 | 1993 | 18 | 0.010 |
Why?
| | Xylazine | 1 | 1993 | 14 | 0.010 |
Why?
| | CD4-CD8 Ratio | 1 | 1992 | 24 | 0.010 |
Why?
| | Cholesterol, Dietary | 1 | 1992 | 15 | 0.010 |
Why?
| | Cold Temperature | 1 | 1993 | 196 | 0.010 |
Why?
| | Neoplasm Transplantation | 1 | 1992 | 250 | 0.010 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 1992 | 174 | 0.010 |
Why?
| | Obesity | 1 | 2004 | 3008 | 0.010 |
Why?
| | Lymphocyte Activation | 1 | 1995 | 1150 | 0.010 |
Why?
| | Tumor Cells, Cultured | 1 | 1992 | 962 | 0.000 |
Why?
| | Dietary Fats | 1 | 1992 | 300 | 0.000 |
Why?
| | Actuarial Analysis | 1 | 1984 | 22 | 0.000 |
Why?
| | Adolescent | 1 | 1982 | 22130 | 0.000 |
Why?
| | Aged | 1 | 1982 | 24746 | 0.000 |
Why?
| | Electrocardiography | 1 | 1984 | 618 | 0.000 |
Why?
| | Recurrence | 1 | 1984 | 1111 | 0.000 |
Why?
| | Middle Aged | 1 | 1982 | 34647 | 0.000 |
Why?
|
|
Watkins's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|